Resorufin analogs preferentially bind cerebrovascular amyloid: Potential use as imaging ligands for cerebral amyloid angiopathy

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Han, Byung Hee ^a   Zhou, Meng Liang ^a   Vellimana, Ananth K ^a   Milner, Eric ^a   Kim, David H ^a   Greenberg, Jacob K ^a   Chu, Wenhua ^a   MacH, Robert H ^a   Zipfel, Gregory J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid beta; amyloid imaging; Cerebral amyloid angiopathy; dementia; diagnosis; phenoxazines; positron emission tomography; resorufin; tracer

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PROTEIN; BENZYLOXYRESORUFIN; ETHOXYRESORUFIN; FLUORESCENT DYE; LIGAND; LIPID; METHOXY X34; RADIOLIGAND; RESORUFIN; RESORUFIN DERIVATIVE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; OXAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BINDING AFFINITY; BRAIN BIOPSY; BRAIN BLOOD VESSEL; BRAIN TISSUE; CHEMICAL MODIFICATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MOUSE; MULTIPHOTON MICROSCOPY; NEUROIMAGING; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SENILE PLAQUE; SOLUBILITY; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS; VASCULAR SMOOTH MUSCLE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL; CHEMISTRY; METABOLISM; METHODOLOGY; PATHOLOGY; PROTEIN BINDING;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL AMYLOID ANGIOPATHY; HUMANS; MICE; MICE, TRANSGENIC; OXAZINES; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING;

EID: 84055213660     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-86     Document Type: Article

References (53)

1. Alzheimer's disease: perspectives for the new millennium. Sisodia SS, J Clin Invest 1999 104 1169 1170 10.1172/JCI8508 10545514 (Pubitemid 29536286)
2. Molecular and Cellular Mechanisms for Alzheimer's Disease: Understanding APP Metabolism. Zhang YW, Xu H, Curr Mol Med 2007 7 687 696 10.2174/ 156652407782564462 18045146 (Pubitemid 350201668)
3. Alzheimer's disease: genes, proteins, and therapy. Selkoe DJ, Physiol Rev 2001 81 741 766 11274343 (Pubitemid 32267077)
4. Abeta40 inhibits amyloid deposition in vivo. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E, J Neurosci 2007 27 627 633 10.1523/JNEUROSCI.4849-06.2007 17234594 (Pubitemid 46143766)
5. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T, Neuron 2005 47 191 199 10.1016/j.neuron.2005.06.030 16039562 (Pubitemid 41019251)
6. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM, J Neurosci 2005 25 2803 2810 10.1523/JNEUROSCI.5170- 04.2005 15772340 (Pubitemid 40389238)
7. Amyloid beta-protein length and cerebral amyloid angiopathy-related haemorrhage. McCarron MO, Nicoll JA, Stewart J, Cole GM, Yang F, Ironside JW, Mann DM, Love S, Graham DI, Neuroreport 2000 11 937 940 10.1097/00001756- 200004070-00008 10790859 (Pubitemid 30235432)
8. Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. Domnitz SB, Robbins EM, Hoang AW, Garcia-Alloza M, Hyman BT, Rebeck GW, Greenberg SM, Bacskai BJ, Frosch MP, J Neuropathol Exp Neurol 2005 64 588 594 16042310 (Pubitemid 40995273)
9. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews PM, Jucker M, Nat Neurosci 2004 7 954 960 10.1038/nn1302 15311281 (Pubitemid 39129504)
10. Clinical phenotypes of Cerebral Amyloid Angiopathy. Maia LF, Mackenzie IR, Feldman HH, J Neurol Sci 2007 257 23 30 10.1016/j.jns.2007.01.054 17341423 (Pubitemid 46856515)
11. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO, Neurobiol Aging 2004 25 589 597 discussion 603-584 10.1016/j.neurobiolaging.2004.02.003 15172734 (Pubitemid 38686478)
12. Cerebral amyloid angiopathy. A critical review. Vinters HV, Stroke 1987 18 311 324 10.1161/01.STR.18.2.311 3551211 (Pubitemid 17059655)
13. Cerebral amyloid angiopathy and vessel dysfunction. Greenberg SM, Cerebrovasc Dis 2002 13 Suppl 2 42 47 11901242 (Pubitemid 34233908)
14. Clinicopathologic studies of primary cerebral amyloid angiopathy. Okazaki H, Reagan TJ, Campbell RJ, Mayo Clin Proc 1979 54 22 31 759733 (Pubitemid 9116377)
15. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Greenberg SM, Vonsattel JP, Stakes JW, Gruber M, Finklestein SP, Neurology 1993 43 2073 2079 8413970 (Pubitemid 23318883)
16. Silent brain infarcts and the risk of dementia and cognitive decline. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM, N Engl J Med 2003 348 1215 1222 10.1056/NEJMoa022066 12660385 (Pubitemid 36359297)
17. Cerebral amyloid angiopathy in the elderly: the clinicopathological features, pathogenesis, and risk factors. Itoh Y, Yamada M, Journal of medical and dental sciences 1997 44 11 19 9385038 (Pubitemid 127705654)
18. Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Mann DM, Iwatsubo T, Ihara Y, Cairns NJ, Lantos PL, Bogdanovic N, Lannfelt L, Winblad B, Maat-Schieman ML, Rossor MN, Am J Pathol 1996 148 1257 1266 8644866
19. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Knudsen KA, Rosand J, Karluk D, Greenberg SM, Neurology 2001 56 537 539 11222803 (Pubitemid 32172884)
20. Amyloid binding ligands as Alzheimer's disease therapies. Lee VM, Neurobiol Aging 2002 23 1039 1042 10.1016/S0197-4580(02)00121-5 12470800 (Pubitemid 35447785)
21. Neuroimaging in dementia: in vivo amyloid imaging. Suhara T, Higuchi M, Miyoshi M, The Tohoku journal of experimental medicine 2008 215 119 124 10.1620/tjem.215.119 18577840
22. Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography. Henriksen G, Yousefi BH, Drzezga A, Wester HJ, European journal of nuclear medicine and molecular imaging 2008 35 Suppl 1 75 81 18224319
23. Amyloid imaging in Alzheimer's disease. Nordberg A, Current opinion in neurology 2007 20 398 402 10.1097/WCO.0b013e3281a47744 17620873 (Pubitemid 47051985)
24. Amyloid plaque imaging in vivo: current achievement and future prospects. Nordberg A, European journal of nuclear medicine and molecular imaging 2008 35 Suppl 1 46 50 18188557
25. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B, Ann Neurol 2004 55 306 319 10.1002/ana.20009 14991808 (Pubitemid 38269583)
26. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, Fox NC, Rossor MN, Ann Neurol 2006 60 145 147 10.1002/ana.20889 16802294
27. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, Oikonen V, Kailajarvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO, Neurology 2006 1575 1580 (Pubitemid 44747926)
28. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Neurology 2006 67 446 452 10.1212/01.wnl.0000228230.26044.a4 16894106 (Pubitemid 44214969)
29. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A, Brain 2006 129 2856 2866 10.1093/brain/awl178 16854944 (Pubitemid 44684508)
30. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum TE, Kilbourn MR, Skovronsky D, Kung HF, J Nucl Med 2009 50 1887 1894 10.2967/jnumed.109.065284 19837759
31. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasic JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ, J Nucl Med 2010 51 913 920 10.2967/jnumed.109.069088 20501908
32. Use of florbetapir-PET for imaging beta-amyloid pathology. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Reiman PEM, Zehntner SP, Skovronsky DM, Group AAS, JAMA 2011 305 275 283 10.1001/jama.2010.2008 21245183
33. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G, Science 1996 274 99 102 10.1126/science.274.5284.99 8810256 (Pubitemid 26332733)
34. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG, J Neurosci 2001 21 372 381 11160418 (Pubitemid 32107428)
35. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ, J Neurosci 2008 28 13542 13550 10.1523/JNEUROSCI.4686-08.2008 19074028
36. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE, Bioorganic & medicinal chemistry letters 2002 12 295 298 10.1016/S0960-894X(01)00734-X 22197998 (Pubitemid 34113887)
37. Cholesterol in the senile plaque: often mentioned, never seen. Lebouvier T, Perruchini C, Panchal M, Potier MC, Duyckaerts C, Acta neuropathologica 2009 117 31 34 10.1007/s00401-008-0448-1 18985365
38. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Hawkes CA, McLaurin J, Proc Natl Acad Sci USA 2009 106 1261 1266 10.1073/pnas.0805453106 19164591
39. Antibody-mediated clearance of amyloid-beta peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. Prada CM, Garcia-Alloza M, Betensky RA, Zhang-Nunes SX, Greenberg SM, Bacskai BJ, Frosch MP, J Neurosci 2007 27 1973 1980 10.1523/JNEUROSCI.5426-06.2007 17314293
40. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB, J Neurosci 2005 25 629 636 10.1523/JNEUROSCI.4337-04.2005 15659599
41. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D, Basi G, Schenk D, Seubert P, Games D, J Neurosci 2008 28 6787 6793 10.1523/JNEUROSCI.2377-07.2008 18596154
42. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE, Greenberg SM, Neurology 2009 72 1230 1235 10.1212/01.wnl.0000345666.83318.03 19349602
43. Cerebral Amyloid Angiopathy. Progressive Disruption of the Neurovascular Unit. Zipfel GJ, Han H, Ford AL, Lee JM, Stroke 2008
44. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent - a pilot study. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, Wai YY, Chang HP, Lo CW, Yao CH, Yen TC, Kung MP, Nuclear medicine and biology 2010 37 497 508 10.1016/j.nucmedbio.2010.02.003 20447562
45. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O'Keefe G, Gong SJ, Gunawan RM, Saunder T, Ackerman U, Tochon-Danguy H, Churilov L, Phan TG, Rowe CC, Neurology 2010 74 487 493 10.1212/WNL. 0b013e3181cef7e3 20142615
46. Cerebral microhemorrhage and brain beta-amyloid in aging and Alzheimer disease. Yates PA, Sirisriro R, Villemagne VL, Farquharson S, Masters CL, Rowe CC, Neurology 2011 77 48 54 10.1212/WNL.0b013e318221ad36 21700585
47. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Herzig MC, Van Nostrand WE, Jucker M, Brain Pathol 2006 16 40 54 10.1111/j.1750-3639.2006.tb00560.x 16612981
48. Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. van Horssen J, Otte-Holler I, David G, Maat-Schieman ML, van den Heuvel LP, Wesseling P, de Waal RM, Verbeek MM, Acta neuropathologica 2001 102 604 614 11761721 (Pubitemid 33061791)
49. Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated Abeta40 (DAbeta(1-40)) are modulated by sulfate moieties of heparin. Timmer NM, Schirris TJJ, Bruinsma IB, Otte-Holler I, van Kuppevelt TH, de Waal RMW, Verbeek MM, Neurosci Res 2010 66 380 389 10.1016/j.neures.2009. 12.012 20036698
50. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT, Ann Neurol 2000 47 739 747 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0. CO;2-8 10852539 (Pubitemid 30390194)
51. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT, J Neuropathol Exp Neurol 2002 61 797 805 12230326 (Pubitemid 35001352)
52. BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia. Han BH, D'Costa A, Back SA, Parsadanian M, Patel S, Shah AR, Gidday JM, Srinivasan A, Deshmukh M, Holtzman DM, Neurobiol Dis 2000 7 38 53 10.1006/nbdi.1999.0275 10671321 (Pubitemid 30141818)
53. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. Ryu EK, Choe YS, Lee KH, Choi Y, Kim BT, Journal of medicinal chemistry 2006 49 6111 6119 10.1021/jm0607193 17004725 (Pubitemid 44484955)